Stapled Peptides in Cancer

Stapled peptides represent a class of rationally designed alpha-helical peptides constrained by hydrocarbon cross-links that enhance binding affinity, protease resistance, and cell permeability. Originally developed to disrupt protein-protein interactions deemed undruggable by small molecules, stapled peptides have advanced into clinical oncology trials.

Stapling Chemistry

All-hydrocarbon staples are introduced via ring-closing metathesis of terminal olefin-bearing amino acids, typically S-pentenylglycine or R-octenylglycine, positioned at i, i+4 or i, i+7 positions along the helical face. The resulting macrocycle constrains the peptide backbone into a stable alpha-helical conformation. Stapled peptides demonstrate enhanced resistance to proteolytic degradation and can penetrate cell membranes through mechanisms that are independent of classical endocytic pathways, involving direct biophysical interaction with membrane lipids.

MDM2/MDMX Targeting

The tumor suppressor p53 is negatively regulated by murine double minute 2 (MDM2) and MDMX through direct binding to the p53 transactivation domain. This interaction involves an alpha-helical segment of p53 inserting into a hydrophobic cleft on MDM2/MDMX. Stapled peptides mimicking this helical segment competitively displace p53, restoring its transcriptional activity and triggering apoptosis in tumor cells with wild-type p53.

ALRN-6924

ALRN-6924 is a dual MDM2/MDMX inhibitor stapled peptide that has advanced through phase 1 and phase 2 clinical trials. In acute myeloid leukemia and myelodysplastic syndrome, ALRN-6924 demonstrated dose-dependent p53 activation, with manageable neutropenia as the primary dose-limiting toxicity. The compound achieves intracellular target engagement at nanomolar concentrations in patient-derived samples.

BCL-2 Family Applications

Stapled peptides targeting anti-apoptotic BCL-2 family proteins, including BCL-2, BCL-XL, and MCL-1, have demonstrated potent pro-apoptotic activity in preclinical models. These agents mimic the BH3 death domain, engaging anti-apoptotic proteins and releasing pro-apoptotic effectors. Selectivity for individual BCL-2 family members remains a key design challenge given the structural similarity among these targets.

Future Directions

Combination strategies pairing stapled peptides with immune checkpoint inhibitors, chemotherapy, or targeted therapies may overcome resistance mechanisms. Peptide stability and oral bioavailability continue to require optimization for broader clinical utility.